Top

Published in:

Open Access 01-12-2017 | Research article

Medical and sociodemographic factors predict persistent smoking after coronary events

Authors: Elise Sverre, Jan Erik Otterstad, Erik Gjertsen, Lars Gullestad, Einar Husebye, Toril Dammen, Torbjørn Moum, John Munkhaugen

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Abstract

Background

Understanding the determinants of persistent smoking after a coronary event constitutes the basis of modelling interventions of smoking cessation in secondary prevention programs. We aim to identify the potentially modifiable medical, sociodemographic and psychosocial factors, comprising the study factors, associated with unfavourable risk factor control after CHD events.

Methods

A cross-sectional explorative study used logistic regression analysis to investigate the association between study factors and smoking status in 1083 patients hospitalized with myocardial infarction and/or coronary revascularization. Hospital record data, a self-report questionnaire, clinical examination and blood samples were applied.

Results

At the index hospitalization, 390 patients were smoking and at follow-up after 2–36 months 167 (43%) of these had quit, while 230 reported persistent smoking. In adjusted analyses, unemployed or disability benefits (Odds ratio (OR) 4.1), low education (OR 3.5), longer smoking duration (OR 2.3) and not having ST-elevation myocardial infarction (STEMI) as index event (OR 2.3) were significantly associated with persistent smoking. Psychosocial factors at follow-up were not associated with persistent smoking. Smokers reported high motivation for cessation, with 68% wanting help to quit. Only 42% had been offered nicotine replacement therapy or other cessation aids. Smokers rated use of tobacco as the most important cause of their coronary disease (6.8 on a 1–10 Likert scale).

Conclusions

Low socioeconomic status, prior duration of smoking, and not having STEMI as index event were associated with persisting smoking. Persistent smokers in this study seem to have an acceptable risk perception and were motivated to cease smoking, but needed assistance through cessation programs including prescription of pharmacological aids.

Trial registration

Registered at ClinicalTrials.gov: NCT02309255, registered retrospectively.

Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.CrossRefPubMedPubMedCentral

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23(11):Np1–np96.CrossRefPubMed

Edwards R. The problem of tobacco smoking. BMJ. 2004;328(7433):217–9.CrossRefPubMedPubMedCentral

Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;1:CD003041.

Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414–25.CrossRefPubMed

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.

Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012;5:CD001837.PubMedCentral

Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636–48.CrossRefPubMed

OECD. Saa, in Health at a Glance: Europe 2012. Paris: OECD Publishing; 2012. doi.org/10.1787/9789264183896-24-en. Accessed 3 Feb 2017

10.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40.CrossRefPubMed

11.

Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am J Prev Med. 2010;39(3):228–34.CrossRefPubMed

12.

Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013;34(42):3259–67.CrossRefPubMed

13.

Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle F, Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290–306.CrossRefPubMed

14.

Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295–303.CrossRefPubMedPubMedCentral

15.

Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: patient beliefs and health-related behaviour. J Psychosom Res. 2005;58(5):403–15.CrossRefPubMed

16.

Chiriboga DE, Ockene JK, Ockene IS. Barriers to preventive interventions for coronary heart disease. Cardiol Clin. 2003;21(3):459–70.CrossRefPubMed

17.

Benowitz NL, Prochaska JJ. Smoking cessation after acute myocardial infarction. J Am Coll Cardiol. 2013;61(5):533–5.CrossRefPubMed

18.

Munkhaugen J, Sverre E, Peersen K, Gjertsen E, Gullestad L, Moum T, Otterstad JE, Perk J, Husebye E, Dammen T. The role of medical and psychosocial factors for unfavourable coronary risk factor control. Scand Cardiovasc J. 2016;50(1):1–8.CrossRefPubMed

19.

Charlson ME, Pompei P, K L. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed

20.

Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77.CrossRefPubMed

21.

Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67(1):89–97.CrossRefPubMed

22.

Pallesen S, Nordhus IH, Carlstedt B, Thayer JF, Johnsen TB. A Norwegian adaptation of the Penn State Worry Questionnaire: factor structure, reliability, validity and norms. Scand J Psychol. 2006;47(4):281–91.CrossRefPubMed

23.

Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjornevik M, Morin CM. A new scale for measuring insomnia: the Bergen Insomnia Scale. Percept Mot Skills. 2008;107(3):691–706.CrossRefPubMed

24.

Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res. 2006;60(6):631–7.CrossRefPubMed

25.

Broadbent E, Petrie KJ, Ellis CJ, Anderson J, Gamble G, Anderson D, Benjamin W. Patients with acute myocardial infarction have an inaccurate understanding of their risk of a future cardiac event. Intern Med J. 2006;36(10):643–7.CrossRefPubMed

26.

Gerber Y, Koren-Morag N, Myers V, Benyamini Y, Goldbourt U, Drory Y. Long-term predictors of smoking cessation in a cohort of myocardial infarction survivors: a longitudinal study. Eur J Cardiovasc Prev Rehabil. 2011;18(3):533–41.CrossRefPubMed

27.

Dullaghan L, Lusk L, McGeough M, Donnelly P, Herity N, Fitzsimons D. 'I am still a bit unsure how much of a heart attack it really was!' Patients presenting with non ST elevation myocardial infarction lack understanding about their illness and have less motivation for secondary prevention. Eur J Cardiovasc Nurs. 2014;13(3):270–6.CrossRefPubMed

28.

Prugger C, Wellmann J, Heidrich J, De Bacquer D, De Backer G, Perier MC, Empana JP, Reiner Z, Fras Z, Jennings C, et al. Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. Eur J Prev Cardiol. 2015;22(9):1212–9.CrossRefPubMed

29.

Boggon R, Timmis A, Hemingway H, Raju S, Malvestiti FM, Van Staa TP. Smoking cessation interventions following acute coronary syndrome: a missed opportunity? Eur J Prev Cardiol. 2014;21(6):767–73.CrossRefPubMed

30.

Perk J, Hambraeus K, Burell G, Carlsson R, Johansson P, Lisspers J. Study of Patient Information after percutaneous Coronary Intervention (SPICI): should prevention programmes become more effective? EuroIntervention. 2015;10(11):e1–7.CrossRefPubMed

31.

Mathew AR, Hogarth L, Leventhal AM, Cook JW, Hitsman B. Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model. Addiction. 2017;112(3):401–12.CrossRefPubMed

32.

Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med. 2014;76(1):44–57.CrossRefPubMed

33.

Murphy BM, Grande MR, Navaratnam HS, Higgins RO, Elliott PC, Turner A, Rogerson MC, Worcester MU, Goble AJ. Are poor health behaviours in anxious and depressed cardiac patients explained by sociodemographic factors? Eur J Prev Cardiol. 2013;20(6):995–1003.CrossRefPubMed

34.

Svansdottir E, Karlsson HD, Gudnason T, Olason DT, Thorgilsson H, Sigtryggsdottir U, Sijbrands EJ, Pedersen SS, Denollet J. Validity of Type D personality in Iceland: association with disease severity and risk markers in cardiac patients. J Behav Med. 2012;35(2):155–66.CrossRefPubMed

35.

Mommersteeg PM, Kupper N, Denollet J. Type D personality is associated with increased metabolic syndrome prevalence and an unhealthy lifestyle in a cross-sectional Dutch community sample. BMC Public Health. 2010;10:714.CrossRefPubMedPubMedCentral

36.

Murphy BM, Elliott PC, Higgins RO, Le Grande MR, Worcester MU, Goble AJ, Tatoulis J. Anxiety and depression after coronary artery bypass graft surgery: most get better, some get worse. Eur J Cardiovasc Prev Rehabil. 2008;15(4):434–40.CrossRefPubMed

37.

Ceccarini M, Manzoni GM, Castelnuovo G. Assessing depression in cardiac patients: what measures should be considered? Depress Res Treat. 2014;2014:148256. doi:10.1155/2014/148256.

38.

West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart. 2012;98(8):637–44.CrossRefPubMed

39.

Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med. 2008;168(20):2194–204.CrossRefPubMed

40.

Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;1:CD001800.

41.

Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116(10):682–92.CrossRefPubMed

42.

Snaterse M, Scholte Op Reimer WJ, Dobber J, Minneboo M, Ter Riet G, Jorstad HT, Boekholdt SM, Peters RJ. Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters. Neth Heart J. 2015;23(12):600–7.CrossRefPubMedPubMedCentral

43.

Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual Versus Abrupt Smoking Cessation: A Randomized, Controlled Noninferiority Trial. Ann Intern Med. 2016;164(9):585–92.CrossRefPubMed

44.

Peersen K, Munkhaugen J, Gullestad L, Dammen T, Moum T, Otterstad JE. Reproducibility of an extensive self-report questionnaire used in secondary coronary prevention. Scand J Public Health. 2017;45:269–76.CrossRefPubMedPubMedCentral

Title: Medical and sociodemographic factors predict persistent smoking after coronary events
Authors: Elise Sverre
Jan Erik Otterstad
Erik Gjertsen
Lars Gullestad
Einar Husebye
Toril Dammen
Torbjørn Moum
John Munkhaugen
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-017-0676-1

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Medical and sociodemographic factors predict persistent smoking after coronary events

Abstract

Background

Methods

Results

Conclusions

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

Elevated exhaled acetone concentration in stage C heart failure patients with diabetes mellitus

Deletion of the NR4A nuclear receptor NOR1 in hematopoietic stem cells reduces inflammation but not abdominal aortic aneurysm formation

Low adiponectin is associated with diastolic dysfunction in women: a cross-sectional study from the Tromsø Study

Effects of angiotensin receptor blockers on neointimal characteristics in angina patients requiring stent implantation: optical coherence tomography analysis

Macrophage migration inhibitory factor promoter polymorphisms (−794 CATT5–8): Relationship with soluble MIF levels in coronary atherosclerotic disease subjects

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page